So what is compounded semaglutide? It’s a custom-made version of semaglutide (the same GLP-1 receptor agonist active ingredient in brand names Wegovy and Ozempic). Compounding pharmacies prepare compounded semaglutide instead of manufactured by Novo Nordisk. It is not a generic version and it is not FDA-approved. With GLP-1 use at a record high among adults […]
By Astra Editorial Team
Published:
Updated:
So what is compounded semaglutide? It’s a custom-made version of semaglutide (the same GLP-1 receptor agonist active ingredient in brand names Wegovy and Ozempic). Compounding pharmacies prepare compounded semaglutide instead of manufactured by Novo Nordisk. It is not a generic version and it is not FDA-approved.
With GLP-1 use at a record high among adults in the US, compounded GLP-1s became a large part of that demand. This guide covers what compounded semaglutide is, how it differs from the brand names, whether it works, the risks the FDA has flagged, what it costs, and how to find a legitimate source.
Quick answer: Compounded semaglutide is a made-to-order version of semaglutide prepared by a licensed compounding pharmacy. It uses the same active ingredient as Ozempic and Wegovy but is not FDA-approved or independently tested.
Compounding is when a licensed pharmacy prepares a medication from its component ingredients to fit a specific patient. Compounded semaglutide applies that to semaglutide base, which is the same active ingredient the FDA approved in Ozempic (type 2 diabetes) and Wegovy (weight management).
Because it’s made to order, compounded semaglutide appears in forms the brand names don’t readily offer:
That said, only injectable and oral semaglutide have been studied in humans at established doses.
A 5-minute health profile at Astra gets reviewed by a licensed clinician. If compounded semaglutide fits your case, it ships from VialsRx, a US-licensed 503A pharmacy, with clinical support included.
Start your health profile →Quick answer: Ozempic and Wegovy are FDA-approved, standardized, and made by Novo Nordisk. Compounded semaglutide is pharmacy-made, not FDA-approved, variable in dose and form, and not a generic version of the brand-name GLP-1s.
There are no FDA-approved generics of Ozempic or Wegovy yet. Generics must prove bioequivalence; compounded products skip that process entirely.
| Compounded semaglutide | Ozempic / Wegovy | |
| FDA approved? | No | Yes |
| Made by | Compounding pharmacies (state-regulated 503A) or FDA-registered outsourcing facilities (503B) | Novo Nordisk’s FDA-registered plants |
| Active ingredient | Semaglutide base (salt forms not permitted) | Semaglutide base |
| Delivery | Usually vial + syringe | Prefilled pen (or tablet) |
| Dosing | Variable, including microdoses | Fixed, pre-measured, clinically studied |
For a single-brand breakdown, see compounded semaglutide vs. Ozempic. Comparing molecules instead of brands? Start with semaglutide vs. tirzepatide.
Quick answer: It started during the 2022-2024 Ozempic and Wegovy shortage, when federal law let pharmacies fill the gap. Today, semaglutide is compounded mainly for patients who need a dose, form, or formulation the commercial product doesn’t offer.
When the brand names went into nationwide shortage, section 503A of the Food, Drug, and Cosmetic Act let state-licensed pharmacies compound patient-specific prescriptions, while 503B outsourcing facilities — which follow stricter current good manufacturing practice (CGMP) rules and are FDA-inspected — made larger batches.
As a narrative review in the American Journal of Managed Care notes, this filled a real access gap but introduced quality questions the approved products don’t carry.
Quick answer: Yes, but narrowly. A licensed 503A pharmacy can still compound patient-specific semaglutide when a prescriber documents a clinical need the commercial product can’t meet.
The grace periods for compounders ended by May 2025, and the FDA has since issued warning letters to 30 telehealth companies marketing unapproved versions. What remains legal is patient-specific 503A compounding. Cost alone is not a valid reason, and pharmacies cannot make trivial changes just to sidestep FDA rules.
Quick answer: The active ingredient produces significant weight loss. Real-world data shows about 14% of body weight lost in one year on semaglutide. Compounded semaglutide uses the same molecule, so results are possible, but potency and dosing depend on the pharmacy.
In a 2025 real-world study of nearly 10,000 patients without diabetes, people on semaglutide 2.4 mg lost an average of 14.6 kg (~14%) after one year; tirzepatide users lost about 16.5%. Mechanistically, semaglutide slows gastric emptying, reduces appetite, and increases insulin secretion.
Its benefits also extend beyond weight: in the SELECT trial, semaglutide 2.4 mg cut major cardiovascular events by about 20% in adults with obesity and established heart disease but without diabetes.
All-in. No membership. Licensed clinician reviews every prescription. Filled by a US-licensed 503A pharmacy.
See if you qualify →Important context: those numbers come from FDA-approved semaglutide at studied doses. Compounded versions vary in concentration and dose, and none has been through its own trials, so we can’t guarantee the results will match.
Quick answer: The active ingredient carries the same side effects as brand-name semaglutide, but compounded products add risks the FDA has specifically flagged, such as wrong ingredients, impurities, contamination, and dosing errors. Safety depends heavily on the pharmacy.
As of May 31, 2026, the FDA had received 990 adverse-event reports tied to compounded semaglutide (likely an undercount, since 503A pharmacies are not required to report). Compounding itself has a long-standing, legitimate role in medicine, and much of the added risk comes from the pharmacy and supply chain rather than the molecule, which is why sourcing matters so much.
The specific concerns:
Common side effects mirror the brand names, including nausea, vomiting, diarrhea, constipation, and fatigue, with rarer serious risks including pancreatitis, gallbladder issues, and kidney injury.
Quick answer: Use a provider that requires a prescription and a real evaluation by a licensed clinician, and that names an accredited, licensed compounding pharmacy. Avoid anyone selling it without a prescription or advertising “generic Ozempic.”
Look for:
That’s what the health profile is for. A licensed clinician at Wasef Health, PC reviews your history and tells you honestly whether compounded semaglutide, brand-name, compounded tirzepatide, or something else makes the most sense. No pressure, no upsell.
Talk to a clinician →| Provider | Compounded GLP-1s Offered | Effective monthly for compounded semaglutide (best plan) | Watch for |
|---|---|---|---|
| Astra | Semaglutide, tirzepatide, microdose | from $68/mo (annual plan) | All-inclusive (consult, messaging, shipping, supplies); no membership; flat at every dose |
| Cora | Compounded GLP-1 plans | from $99/mo (annual plan) | Flat pricing |
| TrimRx | Semaglutide / tirzepatide | $174/mo (annual plan) | No membership fee |
| Eden | Compounded semaglutide | $99/mo + membership | Membership: $39 first month, $99/mo after |
| Good Life Meds | Compounded semaglutide | $199/mo | Flat across doses |
| Noom Med | Compounded semaglutide | $129-$249/mo | $129 first month; $249/mo thereafter (billed quarterly) |
Full side-by-side, including brand-name and manufacturer self-pay options, on the GLP-1 Telehealth Price Index.
Quick answer: Astra compounded semaglutide costs $145/mo month-to-month, dropping to $68 per month on the annual plan, for a total of $816. Astra (try-astra.com) offers flat, all-inclusive prices with no membership fee and the same cost at every dose. The rate drops the longer you commit.
| Astra plan (compounded semaglutide) | Per month |
|---|---|
| 12-month plan (best value) | $68/mo ($816 total) |
| 6-month plan | $94/mo |
| 3-month plan | $95/mo |
| Monthly | $145/mo |
What you’ll get at every tier: provider consultation, unlimited doctor messaging, shipping, and supplies. No separate membership fee unlike several competitors above. Prefer tirzepatide? Compounded tirzepatide at Astra runs from $118 per month on the annual plan or $166 per month on the 3-month plan.
Astra pairs licensed clinicians at Wasef Health, PC with a US-licensed 503A pharmacy. Compounded semaglutide from $68/month, all-in.
Start your health profile Takes about 5 minutes.A pharmacy prepared it from a semaglutide base for a specific patient, rather than it being a mass-manufactured, FDA-approved product like Ozempic or Wegovy.
Ozempic is Novo Nordisk’s FDA-approved semaglutide pen, approved for type 2 diabetes, in fixed doses. Compounded semaglutide is a pharmacy-made version, usually a vial, that isn’t FDA-approved or independently tested. See our Ozempic comparison.
Yes, semaglutide produces meaningful weight loss for most people who tolerate it and reach an effective dose, alongside diet and activity. Compounded versions use the same active ingredient, so results are possible but not guaranteed to match trial data.
Common reasons: being early in titration or on too low a dose (including some microdose protocols), inconsistent dosing, a plateau, or a product with lower-than-expected potency. Talk to your prescriber before assuming the medication failed.
Most people lose roughly 5% to 10% of body weight in the first couple of months, so 20 lbs in 8 weeks is aggressive and not typical or guaranteed. Steady loss with dose titration is the goal.
It reduces overall body fat, including visceral (belly) fat, but doesn’t target one area. Fat loss follows total weight loss, not spot reduction.
Often, yes. Studies show many people regain a substantial share of lost weight after stopping because the appetite effects end with the medication. Most clinicians treat it as long-term therapy paired with lifestyle change.
Limit alcohol as it worsens nausea and low blood sugar, don’t combine it with other GLP-1 medications, and tell your prescriber everything you take. Semaglutide slows gastric emptying, which can affect absorption of other oral medications. This isn’t individual medical advice; confirm with your provider.
Through patient-specific 503A compounding when a prescriber documents a clinical reason the commercial product can’t meet. It’s narrower than the shortage-era free-for-all, and legitimate providers require a real evaluation and prescription.
This article is for educational purposes only and does not constitute medical advice. Consult a licensed physician regarding any medical condition or treatment.